

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 09-01-2007

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEK-ENDING 09-9-2006 TO BE PUBLISHED ON 09-1-2007  
IN THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1105/2006	<b><u>04-9-2006</u></b> Wyeth Holdings Corporation USA (Priority 29-9-03 USA) <b>Divisional</b>	“ 6-[(substituted) phenyl] triazolopyrimidines as anticancer agents”
1106/2006	<b><u>05-9-2006</u></b> Wyeth, USA (Priority 12-12-2003 USA) <b>Divisional</b>	“ Pharmaceutically acceptable salts of quinoline useful treating cardio vascular disease”
1107/2006	AstraZeneca AB, Sweden (Priority 15-9-05 GB)	“ Therapeutic agents”
1108/2006	Unilever Plc., England (Priority 19-9-05 India)	“ Improved process for tea manufacture”
1109/2006	Janssen Pharmaceutica N.V., Belgium (Priority 18-12-03 PCT) <b>Divisional</b>	“Pharmaceutically acceptable salts of pyrido-and pyrimidopyrimidine derivative”
1110/2006	Janssen Pharmaceutica N.V., Belgium (Priority 18-12-03 PCT) <b>Divisional</b>	“ An intermediate of pyrido-and pyrimidopyrimidine derivative”
1111/2006	F. Hoffmann La-Roche Ag, Switzerland (Priority 5-6-03 Europe) <b>Divisional</b>	“ Pharmaceutically acceptable salts of imidazole derivative which are mGluR5 receptor antagonist”
1112/2006	Bristol-Myers Squibb company, USA (Priority 20-8-02 USA) <b>Divisional</b>	“ A pharmaceutical composition comprising aripiprazole and a substituted B-cyclodextrin”

1113/2006	Janssen Pharmaceutica N.V., Belgium (Priority 25-6-02 USA) <b>Divisional</b>	“ Novel substituted quinoline derivative which is in a stereochemically isomeric form”
1114/2006	Janssen Pharmaceutica N.V., Belgium (Priority 25-6-2002 USA) <b>Divisional</b>	“ Pharmaceutically acceptable acid or base addition salt of a novel quinoline derivative”
1115/2006	Sumitomo Chemical Company, Japan (Priority 25-3-03 Japan) <b>Divisional</b>	“ A pyrazol compound and a composition comprising thereof for controlling noxious arthropod pests”
1116/2006	Honda Motor Co, Ltd., Japan (Priority 9-9-05 Japan)	“ Two-cycle Engine”
1117/2006	Nitto Denko Corporation, Japan (Priority 5-9-05 Japan)	“ Percutaneous absorption-type pharmaceutical”
	<b><u>06-9-2006</u></b>	
1118/2006	Bayer CropScience GmbH, Germany (Priority 08-9-05 Europe)	“ Storage-stable formulations of sulfonamides”
1119/2006	Bayer CropScience GmbH, Germany (Priority 08-9-05 Europe)	“ Novel sulfonamide-comprising solid formulations”
1120/2006	Bayer CropScience GmbH, Germany (Priority 08-9-05 Europe)	“ Novel sulfonamide-comprising solid formulations”
1121/2006	1. Fahad Mahboob, 2. Muhammad Ali 3. Beena Akhter 4. Maleeha Syed Gulshan-e-Iqbal, Karachi, Pakistan	“ Straightener to remove compound distortions in wefts and printed designs”
1122/2006	1. Amgen Fremont Inc, 2. Pfizer Inc, USA (Priority 07-9-05 USA)	“ Human monoclonal antibodies activin receptor-like kinase-1”

1123/2006	LES Laboratoires Sevier, France (Priority 09-9-05 France)	“ New association between agomelatine and a noradrenaline reuptake inhibitor and pharmaceutical compositions containing it”
1124/2006	Otsuka Pharmaceutical Co. Ltd., Japan (Priority 15-10-03 Japan <b>Divisional</b> )	“ A salt of 1-substituted -4-nitroimidazole compound”
1125/2006	LES Laboratoires Sevier, France (Priority 09-9-05 France)	“ Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient”
1126/2006	LES Laboratoires Sevier, France (Priority 09-9-05 France)	“ New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it”
1127/2006	Wyeth, USA (Priority 07-9-05 USA)	“ Transdermal drug delivery devices”
1128/2006	Wyeth, USA (Priority 07-9-05 USA)	“ Topical Formulations”
1129/2006	Wyeth, USA (Priority 09-9-05 USA)	“ Pharmaceutical dosage forms and compositions”
1130/2006	Plexxikon Inc, USA (Priority 07-9-05 USA)	“ PPAR active compounds”
1131/2006	Furrukh Zaheer, Karachi, Pakistan	“ Mechanical assembly that forms a leak proof seal between flat and rotating surfaces to prevent high pressure leakage which is used in the marine pumps and compressors”
1132/2006	<b><u>07-9-2006</u></b> Sumitomo Chemical Company, Limited.,	“ A pyrimidine compound and a composition containing the same for

	Japan (Priority 12-5-03 Japan) <b>Divisional</b>	controlling pests”
1133/2006	Bayer CropScience Ag., Germany (Priority 09-9-05 Germany)	“ Solids formulation of fungicidal mixtures”
1134/2006	Bayer CropScience Germany (Priority 09-9-05 Germany)	“ Use of lactate esters for improving the activity of crop protection compositions”
1135/2006	H. Lundbeck A/S., Denmark (Priority 08-9-05 Denmark)	“ Stable solid formulation of sertindole”
1136/2006	Bristol-Myers Squibb Company, USA (Priority 03-2-2000 USA) <b>Divisional</b>	“ Salt of novel taxane derivative, its use as antitumor agent and pharmaceutical composition”
1137/2006	Merck & Co., Inc., USA (Priority 4-6-03 USA) <b>Divisional</b>	“ A pharmaceutically acceptable salt of n-substituted nonaryl-heterocyclic NMDA/NR2B antagonist”
1138/2006	Tanabe Seiyaku Co., Ltd., Japan (Priority 31-8-2000 USA) <b>Divisional</b>	“ Salt of phenylalanine derivative”
1139/2006	AstraZeneca AB, Sweden (Priority 19-9-03 GB) <b>Divisional</b>	““ A pharmaceutically acceptable salt of a quinazoline derivative”
1140/2006	Merck & Co., Inc., USA (Priority 10-6-02 USA) <b>Divisional</b>	“ A pharmaceutically acceptable salt of 11-beta-hydroxysteroid 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia”
1141/2006	AstraZeneca AB, Sweden (Priority 26-1-2000 GB) <b>Divisional</b>	“ A pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid”
1142/2006	SmithKline Beecham	“ Novel Compounds”

Corporation,  
USA  
(Priority 9-9-05 GB)

- 08-9-2006**
- 1143/2006 SAGA Sports (Pvt) Ltd.,  
Sialkot, Pakistan “ Newly invented “Z” cut 22 panel for the construction of outer cover of football”
- 1144/2006 Glaxo Group Ltd.,  
United Kingdom  
(Priority 27-3-02 GB)  
**Divisional** “ A pharmaceutically acceptable salt of a quinoline compound having pharmacological activity, process for its preparation and a composition comprising thereof”
- 1145/2006 Novartis AG,  
Switzerland  
(Priority 13-9-05 GB) “ Combinations comprising a vegf receptor inhibitor”
- 09-9-2006**
- 1146/2006 AstraZeneca AB,  
Sweden  
(Priority 05-4-2002 GB)  
**Divisional** “ A pharmaceutically acceptable salt of benzamide derivative”
- 1147/2006 AstraZeneca AB,  
Sweden  
(Priority 21-12-2000 Europe))  
**Divisional** “ Salt of piperidine and piperazine substituted N-hydroxyformamide as inhibitor of metalloproteinases”
- 1148/2006 Bristol-Myers Squibb Company,  
USA  
(Priority 20-5-2002 USA)  
**Divisional** “ Pyrazolo-pyrimidine aniline compound useful as kinase inhibitor”
- 1149/2006 F.Hoffmann-La Roche AG,  
Switzerland  
(Priority 22-8-97 USA)  
**Divisional** “ A pharmaceutical acceptable salt of imidazole derivative which are mGluR5 receptor antagonist”
- 1150/2006 Bayer CropScience AG,  
Germany  
(Priority 09-9-05 Germany) “ Oil-based suspension concentrates”
- 1151/2006 Syngenta Participations AG.,  
Switzerland “ Container”

(Priority 9-9-05 USA)

1152/2006	Bayer HealthCare AG., Germany (Priority 24-3-04 Europe) <b>Divisional</b>	“ A tautomeric or stereoisomeric form or a physiologically acceptable salt of 2-phenoxy-and 2-phenylsulfonamide derivative with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders”
-----------	--	--

**SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139052	SB Pharmco Puerto Rico Inc., Puerto Rico	608/2004
139053	Novartis Consumer Health S.A. Switzerland	617/2004
139054	Wyeth Holdings Corporation., USA	638/2004
139055	DSM 1P Assets B.V., The Netherlands	889/2004
139056	Zippo Manufacturing company,	898/2004

USA

139057      Wyeth Holdings Corporation,      170/2006  
USA

139058      Wyeth Holdings Corporation,      171/2004  
USA

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Tel: 9215488